Article

It is too Early to Say NO IMMUNOTHERAPY for EGFR‐Mutant NSCLC Patients

2023-09-08

Abstract excerpt

EGFR tyrosine kinase inhibitors (TKIs) are the preferred initial treatment for non-small cell lung cancer (NSCLC) patients harboring EGFR mutations. However, remission is transient, and no further effective treatment options are available for EGFR-TKI-advanced EGFR-mutant NSCLCs. Immunotherapy with immune checkpoint inhibitors (ICIs) induces sustained cancer remission in a subset of NSCLCs. However, ICI therapy ex...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 762b9282-f8b6-5534-96a8-5e00a94c9ced
DOI: 10.20944/preprints202309.0571.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

It is too Early to Say NO IMMUNOTHERAPY for EGFR‐Mutant NSCLC PatientsDOI 10.20944/preprints202309.0571.v1Read

Persist or resist: Immune checkpoint inhibitors in EGFR ‐mutated NSCLCSemantic proximity Read

Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?Semantic proximity Read

[Progress of Immunotherapy in EGFR-mutated Advanced Non-small Cell Lung Cancer].Semantic proximity Read

Efficacy and mechanisms of immune checkpoint inhibitors in late-stage EGFR-mutated non-small cell lung cancer following targeted therapy resistance.Semantic proximity Read

<p>Immunotherapy after EGFR‑TKI treatment in advanced non‑small cell lung cancer: Current status and future perspectives (Review)</p>.Semantic proximity Read

Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutationsSemantic proximity Read

Immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: A systematic review.Semantic proximity Read

Immunotherapy in advanced non-small-cell lung cancer with EGFR mutations.Semantic proximity Read

The efficacy and possible mechanisms of immune checkpoint inhibitors in treating non-small cell lung cancer patients with epidermal growth factor receptor mutation.Semantic proximity Read

[Application of Immune Checkpoint Inhibitors in EGFR Mutant Advanced Non-small Cell Lung Cancer].Semantic proximity Read

Perioperative immunotherapy for patients with EGFR mutant non-small cell lung cancer: Unexpected potential benefits.Semantic proximity Read

[Study Progression on Non-small Cell Lung Cancer with EGFR Mutation Treated by Immune Checkpoint Inhibitors].Semantic proximity Read